Synonym
LG-121071; LG 121071; LG121071; LGD-121071; LGD 121071; LGD121071.
IUPAC/Chemical Name
6-Ethyl-4-(trifluoromethyl)-1,2,6,7,8,9-hexahydropyrido[3,2-g]quinolin-2-one
InChi Key
SZPPQFARTYXRKU-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H15F3N2O/c1-2-8-3-4-19-12-7-13-10(5-9(8)12)11(15(16,17)18)6-14(21)20-13/h5-8,19H,2-4H2,1H3,(H,20,21)
SMILES Code
O=C1NC2=C(C=C(C(CC)CCN3)C3=C2)C(C(F)(F)F)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Unlike testosterone, but similarly to DHT, LG-121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects. In accordance, they are said to possess full anabolic activity with reduced androgenic activity, similarly to anabolic-androgenic steroids. The in vitro metabolism of LG-121071 has been characterized in anticipation of its possible use as a doping agent.
Biological target:
LG-121071, also known as LGD-121071, is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
296.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Thevis M, Schänzer W. Detection of SARMs in doping control analysis. Mol Cell
Endocrinol. 2017 Jan 27. pii: S0303-7207(17)30053-9. doi:
10.1016/j.mce.2017.01.040. [Epub ahead of print] PubMed PMID: 28137616.
2: Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK. Discovery of a
potent, orally active, nonsteroidal androgen receptor agonist:
4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline
(LG121071). J Med Chem. 1999 Jan 28;42(2):210-2. PubMed PMID: 9925725.
3: Knoop A, Krug O, Vincenti M, Schänzer W, Thevis M. In vitro metabolism studies
on the selective androgen receptor modulator (SARM) LG121071 and its
implementation into human doping controls using liquid chromatography-mass
spectrometry. Eur J Mass Spectrom (Chichester). 2015;21(1):27-36. doi:
10.1255/ejms.1328. PubMed PMID: 25906032.
4: Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK. Discovery of a
potent, orally active, nonsteroidal androgen receptor agonist:
4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline
(LG121071). J Med Chem. 1999 Jan 28;42(2):210-2. PubMed PMID: 9925725.
